Ann: Quarterly Activities Report, page-26

First 26 Last

Share
Profile

Follow
Metalduster

7,912 Posts.

392

23/01/20

09:36

Post #: 42530242
Share

Originally posted by Thesi: ↑

My comment above is backed by the announcement.

View attachment 1950097
With a forecasted production rate of 90,000 to 105,000 tonnes.

By not going downstream and producing lithium chemicals again the company is at the mercy of the converters and customers that have stopped purchasing Mt Cattlin production.

Sal De Vida has been crippled to a test tube that the company will continue to plunge money into in the knowledge that it will not produce any revenue for the company once it is complete.

The company is no longer talking about Q2-Q3 for a final investment decision at Sal De Vida, this has been pushed back to "early" in the second half of the year.

It's a depressing and bleak outlook that the company is presenting.

A surplus of production and rising inventory stockpiles of lithium raw materials were key supply side challenges in 2019 and a key driver of the decline in lithium prices. The challenge posed by excess stockpiles is expected to persist throughout the early part of 2020.

Though there was a glimmer of hope...

Investment in upstream projects was stifled in H2 2019, with the current pricing environment insufficient to incentivise further expenditure. In contrast, the level of downstream investment in lithium-ion battery manufacturing and OEM production lines continued to accelerate. This mismatch in upstream investment should accelerate the reversal of the market back to deficit given the lead times associated with upstream project construction and ramp-up are likely to mean incremental supply will be insufficient to meet demand growth in the medium term.

Where that doesn't advantage Galaxy is that Sal De Vida will still be a test tube project and a part of the delayed construction and ramp up.

But, the company could play this well and receive investment to cover the cost to build entirely which was hoped for in the previous discussions that produced no results.

Expand

"But, the company could play this well and receive investment to cover the cost to build entirely which was hoped for in the previous discussions that produced no results."

Thesi
I'm not as clued up as others here but my opinion is go with the staged process and not build in one hit.

Too much can go wrong but in saying that if they bring in an experienced Partner in this game then maybe.

Md

GXY Price at posting: $1.16 Sentiment: Buy Disclosure: Held
4 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BUX

Buxton projects new graphite province discovery at WA Narryer play

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

There are more pages in this discussion • 178 more messages in this thread...

First 26 Last

Add GXY (ASX) to my watchlist

Ann: Quarterly Activities Report, page-26

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

BCI reaches close of funding facility for salt-first part of Mardie project

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Buxton projects new graphite province discovery at WA Narryer play

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Featured News